Avricore Health (TSX-V:AVCR, OTC:AVCRF) Inc was recognized as one of the 2023 Venture 50, the TSX Venture Exchange’s list of top-performing companies.
“To make the Venture 50 feels great and the whole team is excited to keep delivering on our promise to build the world’s largest rapid-testing network in pharmacy,” said Hector Bremner, CEO of Avricore Health (TSX-V:AVCR, OTC:AVCRF), in a statement.
Bremner thanked the firm’s partners and supporters “for helping us make this dream of success become a reality.”
READ: Avricore Health hits record unaudited revenue surpassing $2M in 2022; expects strong revenue growth in 2023
Avricore was selected out of over 1,700 businesses currently listed on the TSX Venture Exchange for its stellar growth in market capitalization, share price appreciation and trading volume, according to a release from the company.
The firm attributed the results largely to the scale up and expansion of HealthTab, its point-of-care testing platform, which is on track to becoming the world’s largest, most reliable network in community pharmacies.
Avricore said it is planning to have HealthTab in “hundreds of new locations and even new countries,” which is expected to drive significant increases in revenues.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas